Aardvark Therapeutics Faces FDA Hurdles as ARD-101 Program Stalls
Event summary
- Aardvark Therapeutics reported $73.9M in cash as of June 30, 2026, sufficient for operations into late 2027.
- The company terminated Phase 3 HERO and OLE trials for ARD-101 in PWS and does not intend to resume them as designed.
- FDA placed a full clinical hold on the ARD-101 program in May 2026, halting all ongoing clinical studies.
- Second-quarter R&D expenses decreased by $2.7M year-over-year due to reduced external study costs.
The big picture
Aardvark's struggles with the FDA highlight the precarious position of clinical-stage biopharmaceutical companies reliant on single therapeutic candidates. The termination of key trials and regulatory hurdles underscore the execution risks in developing novel treatments for rare diseases like PWS, where patient populations are small but unmet medical needs are significant.
What we're watching
- Regulatory Resolution
- Whether Aardvark can successfully navigate FDA discussions to lift the clinical hold on ARD-101.
- Data Assessment Impact
- How the unblinded data from HERO and OLE trials will influence future development decisions for PWS treatment.
- Financial Sustainability
- The pace at which Aardvark burns through its remaining cash reserves given reduced operational scale.